Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Advanced Course on Lung Cancer in Immunotherapy

ESMO Advanced Course on Lung Cancer Immunotherapy 1000x250
Start date
03 Jul 2019
End date
04 Jul 2019
Location
Zurich, Switzerland

Learning objectives

  • Understanding the key players in tumour immunology
  • Getting up-to-date on the role of immunotherapy in advanced NSCLC
  • The role of biomarkers in selecting NSCLC patients for IT
  • Mechanism of combining angiogenesis inhibition with checkpoint inhibition
  • Management of IT toxicity and use of IT in specific subgroups of patients

Download the programme

Accreditation

The programme of this event has been accredited with 10 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.

Co-Chairs

  • John B. Haanen, Netherlands
  • Aurélien Marabelle, France

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.